![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, July 11, 2014 7:37:04 PM
1) NNVC is not in the business of doing basic research science. NNVC's business model is well beyond the point of basic research science. Its business model is built on basic research science done decades ago and patented by TheraCour Pharma.
2)NNVC's business model is based on applying the basic science developed by TheraCour in a marketable way in order to treat (cure) certain viral conditions. Many of the applications developed by NNVC for such treatments have been patented by the company.
NNVC's business has exclusive rights to marketing TheraCour's patented basic research (with limited exceptions), and is protected by its own patents regarding applications of TheraCour's research in actual application to viral treatments (cure).
Like most science, many layers of research have been built; one upon another, to get to the point where NNVC is today. If one has questions about the science, one just needs to go to NNVC's website. There are many good explanations concerning NNVC's science and method of operation.
Some comments have been made concerning repeatability and scientific proof. NNVC has successfully demonstrated the science it uses in over 5,000 animal studies. Proven and repeated 5,000 times in animals. Much more proven and repeated even before animal testing performed.
There is more study and research to do and being done. No mystery, no drama, just process and procedure--mostly by FDA protocol. This process is underway. NNVC is doing some, research partners more. Results are inevitable.
Past evidence suggests that it is likely NNVC's technological platform will be successful. Evidence suggests efficacy and safety as probable, likely outcomes. Could there be negative surprises? Yes. That is why more testing is being done. Again, no mystery, no drama. No certainties, just high probabilities.
For investors: High probabilities, times hugh market potential, equals the potential for high returns. Yes risks. But, high potential returns. Thus very, good risk/reward potential.
Now everyone, do your own research. If you haven't been to NNVC's web site, that is an excellent place to start.
If one prefers to view things in a more fantastical way, I recommend the movie from the 1960's, "The Fantastic Voyage". The cides are like smaller than cellular sized virus killing, customizable bots. Welcome to the future. What man can conceive, man can achieve.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM